The retinoblastoma tumor suppressor protein (pRB) is a known regulator of cell-cycle control; however, recent studies identified critical functions for pRB in regulating cancer-associated gene networks that influence the DNA damage response, apoptosis, and cell metabolism. Understanding the impact of these pRB functions on cancer development and progression in the clinical setting will be essential, given the prevalence of pRB loss of function across disease types. Moreover, the current state of evidence supports the concept that pRB loss results in pleiotropic effects distinct from tumor proliferation. Here, the implications of pRB loss (and resultant pathway deregulation) on disease progression and therapeutic response will be reviewed, based on clinical observation. Developing a better understanding of the pRB-regulated pathways that underpin the aggressive features of pRB-deficient tumors will be essential for further developing pRB as a biomarker of disease progression and for stratifying pRB-deficient tumors into more effective treatment regimens.
CITATION STYLE
Mandigo, A. C., Tomlins, S. A., Kelly, W. K., & Knudsen, K. E. (2022, January 15). Relevance of pRB Loss in Human Malignancies. Clinical Cancer Research. American Association for Cancer Research Inc. https://doi.org/10.1158/1078-0432.CCR-21-1565
Mendeley helps you to discover research relevant for your work.